share_log

Bruush Oral Care | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Yaletown Bros. Ventures Ltd.(30%),Matthew Friesen(30%), etc.

SEC announcement ·  Feb 9 16:38
Summary by Moomoo AI
On February 5, 2024, Yaletown Bros. Ventures Ltd, along with individuals Matthew Friesen and Bradley Friesen, filed an amendment to Schedule 13D with the United States Securities and Exchange Commission, indicating a significant change in their holdings of Bruush Oral Care Inc. common shares. The group collectively owns approximately 30% of Bruush Oral Care, which includes 33,000,000 common shares issuable upon the exercise of Pre-Funded Warrants. The Friesens, both Canadian citizens, have joint control over Yaletown Bros. Ventures Ltd and are engaged in investment management. From October 11, 2023, to October 24, 2023, their ownership ranged from 63% to 82% of the company's securities. However, recent transactions have seen the Reporting Persons sell a total of 1,776,986 common shares in the open market. The sales took place between February 5 and February 8, 2024, with prices ranging from $0.1051 to $0.1137 per share. The amendment to Schedule 13D includes a Joint Filing Agreement dated February 9, 2024.
On February 5, 2024, Yaletown Bros. Ventures Ltd, along with individuals Matthew Friesen and Bradley Friesen, filed an amendment to Schedule 13D with the United States Securities and Exchange Commission, indicating a significant change in their holdings of Bruush Oral Care Inc. common shares. The group collectively owns approximately 30% of Bruush Oral Care, which includes 33,000,000 common shares issuable upon the exercise of Pre-Funded Warrants. The Friesens, both Canadian citizens, have joint control over Yaletown Bros. Ventures Ltd and are engaged in investment management. From October 11, 2023, to October 24, 2023, their ownership ranged from 63% to 82% of the company's securities. However, recent transactions have seen the Reporting Persons sell a total of 1,776,986 common shares in the open market. The sales took place between February 5 and February 8, 2024, with prices ranging from $0.1051 to $0.1137 per share. The amendment to Schedule 13D includes a Joint Filing Agreement dated February 9, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more